Tian Ming Tu

Tian Ming Tu

Auto-generated profile, based on publicly available information

Tian Ming Tu

Department of Neurology, National Neuroscience Institute, Singapore

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
TTTian Ming Tu
Tian Ming Tu
CGClaire Goh
Claire Goh
Ying TanYing Tan
Ying Tan
ALAloysius Sheng‑Ting Leow
Aloysius Sheng‑Ting Leow
YPYu Zhi Pang
Yu Zhi Pang
LYleonard Litt Yeo yeo
leonard Litt Yeo yeo

1 April 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
TTTian Ming Tu
Tian Ming Tu
CSChristopher Ying Hao Seet
Christopher Ying Hao Seet
JKJasmine Shimin Koh
Jasmine Shimin Koh
CTCarol Huilian Tham
Carol Huilian Tham
HCHui Jin Chiew
Hui Jin Chiew
LYLeonard Leong Litt Yeo
Leonard Leong Litt Yeo
As the COVID-19 pandemic progresses, many asymptomatic or mildly symptomatic cases of COVID-19 infection have been identified, either by contact tracing1-3 or through surveillance programs, in various risk-stratified population groups.4-6 At the same time, there have been reports of symptoms emerging or persisting long after the resolution of the original acute infection, which have been described as long-haul symptoms of COVID-19.7

22 November 2018 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
STShilpa Tyagi
Shilpa Tyagi
GKGerald Choon-Huat Koh
Gerald Choon-Huat Koh
LNLuo Nan
Luo Nan
KTKelvin Bryan Tan
Kelvin Bryan Tan
Helen Marie HoenigHelen Marie Hoenig
Helen Marie Hoenig
CTChuen Seng Tan
Chuen Seng Tan
It is essential to study post-stroke healthcare utilization trajectories from a stroke patient caregiver dyadic perspective to improve healthcare delivery, practices and eventually improve long-term outcomes for stroke patients. However, literature addressing this area is currently limited. Addressing this gap, our study described the trajectory of healthcare service utilization by stroke patients and associated costs over 1-year post-stroke and examined the association with caregiver identity and clinical stroke factors. Patient and caregiver variables were obtained from a prospective cohort, while healthcare data was obtained from the national claims database. Generalized estimating equation approach was used to get the population average estimates of healthcare utilization and cost trend across 4 quarters post-stroke. Five hundred ninety-two stroke patient and caregiver dyads were available for current analysis. The highest utilization occurred in the first quarter post-stroke across all service types and decreased with time. The incidence rate ratio (IRR) of hospitalization decreased by 51, 40, 11 and 1% for patients having spouse, sibling, child and others as caregivers respectively when compared with not having a caregiver (p = 0.017). Disability level modified the specialist outpatient clinic usage trajectory with increasing difference between mildly and severely disabled sub-groups across quarters. Stroke type and severity modified the primary care cost trajectory with expected cost estimates differing across second to fourth quarters for moderately-severe ischemic (IRR: 1.67, 1.74, 1.64; p = 0.003), moderately-severe non-ischemic (IRR: 1.61, 3.15, 2.44; p = 0.001) and severe non-ischemic (IRR: 2.18, 4.92, 4.77; p = 0.032) subgroups respectively, compared to first quarter. Highlighting the quarterly variations, we reported distinct utilization trajectories across subgroups based on clinical characteristics. Caregiver availability reducing hospitalization supports revisiting caregiver’s role as potential hidden workforce, incentivizing their efforts by designing socially inclusive bundled payment models for post-acute stroke care and adopting family-centered clinical care practices.

9 March 2017 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
TTTian Ming Tu
Tian Ming Tu
BKBrad J. Kolls
Brad J. Kolls
ESErik J. Soderblom
Erik J. Soderblom
VCViviana Cantillana
Viviana Cantillana
PFPaul Durham Ferrell
Paul Durham Ferrell
DLDaniel T. Laskowitz
Daniel T. Laskowitz
Objective: At present, the absence of a pharmacological neuroprotectant represents an important unmet clinical need in the treatment of ischemic and traumatic brain injury. Recent evidence suggests that administration of apolipoprotein E mimetic therapies represent a viable therapeutic strategy in this setting. We investigate the neuroprotective and anti‐inflammatory properties of the apolipoprotein E mimetic pentapeptide, CN‐105, in a microglial cell line and murine model of ischemic stroke.Methods: Ten to 13‐week‐old male C57/BL6 mice underwent transient middle cerebral artery occlusion and were randomly selected to receive CN‐105 (0.1 mg/kg) in 100 μL volume or vehicle via tail vein injection at various time points. Survival, motor‐sensory functional outcomes using rotarod test and 4‐limb wire hanging test, infarct volume assessment using 2,3,5‐Triphenyltetrazolium chloride staining method, and microglial activation in the contralateral hippocampus using F4/80 immunostaining were assessed at various time points. In vitro assessment of tumor necrosis factor‐alpha secretion in a microglial cell line was performed, and phosphoproteomic analysis conducted to explore early mechanistic pathways of CN‐105 in ischemic stroke.Results: Mice receiving CN‐105 demonstrated improved survival, improved functional outcomes, reduced infarct volume, and reduced microglial activation. CN‐105 also suppressed inflammatory cytokines secretion in microglial cells in vitro. Phosphoproteomic signals suggest that CN‐105 reduces proinflammatory pathways and lower oxidative stress.Interpretation: CN‐105 improves functional and histological outcomes in a murine model of ischemic stroke via modulation of neuroinflammatory pathways. Recent clinical trial of this compound has demonstrated favorable pharmacokinetic and safety profile, suggesting that CN‐105 represents an attractive candidate for clinical translation.

17 March 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
TTTian Ming Tu
Tian Ming Tu
SYShen Jia Yi
Shen Jia Yi
JKJasmine Shimin Koh
Jasmine Shimin Koh
Seyed Ehsan SaffariSeyed Ehsan Saffari
Seyed Ehsan Saffari
RHRebecca Hui Min Hoe
Rebecca Hui Min Hoe
UTUmapathi N. Thirugnanam
Umapathi N. Thirugnanam
Cerebral venous thrombosis (CVT) is a rare but important complication after COVID-19.1,2 In a prospective study involving 47 572 patients with COVID-19, 4 young patients (aged 27 to 38 years) were diagnosed with CVT,3 and CVT occurred more often in COVID-19 infection than the general population.4 More recently, as vaccination against SARS-CoV-2 is used as a public health measure against the COVID-19 pandemic,5 CVT has been reported following vaccination, mostly with the adenovirus vector-based vaccines (Ad26.COV2.S [Janssen/Johnson & Johnson]6 and ChAdOx1-S [Oxford-AstraZeneca]7). CVT after messenger RNA (mRNA)-based vaccines has been reported8,9 but data from observational cohorts have yet to show an increased incidence.10,11 Hence it currently remains unclear if CVT is indeed associated with mRNA-based SARS-CoV-2 vaccines.

21 November 2018 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
YYYen Shing Yeoh
Yen Shing Yeoh
GKGerald Choon-Huat Koh
Gerald Choon-Huat Koh
CTChuen Seng Tan
Chuen Seng Tan
KLKim En Lee
Kim En Lee
TTTian Ming Tu
Tian Ming Tu
NLNan Luo
Nan Luo
Health-related quality of life (HRQoL) is a key metric to understand the impact of stroke from patients’ perspective. Yet HRQoL is not readily measured in clinical practice. This study aims to investigate the extent to which clinical outcomes during admission predict HRQoL at 3 months and 1 year post-stroke. Stroke patients admitted to five tertiary hospitals in Singapore were assessed with Shah-modified Barthel Index (Shah-mBI), National Institute of Health Stroke Scale (NIHSS), Modified Rankin Scale (mRS), Mini-Mental State Examination (MMSE), and Frontal Assessment Battery (FAB) before discharge, and the EQ-5D questionnaire at 3 months and 12 months post-stroke. Association of clinical measures with the EQ index at both time points was examined using multiple linear regression models. Forward stepwise selection was applied and consistently significant clinical measures were analyzed for their association with individual dimensions of EQ-5D in multiple logistic regressions. All five clinical measures at baseline were significant predictors of the EQ index at 3 months and 12 months, except that MMSE was not significantly associated with the EQ index at 12 months. NIHSS (3-month standardized β = − 0.111; 12-month standardized β = − 0.109) and mRS (3-month standardized β = − 0.122; 12-month standardized β = − 0.080) were shown to have a larger effect size than other measures. The contribution of NIHSS and mRS as significant predictors of HRQoL was mostly explained by their association with the mobility, self-care, and usual activities dimensions of EQ-5D. HRQoL at 3 months and 12 months post-stroke can be predicted by clinical outcomes in the acute phase. NIHSS and mRS are better predictors than BI, MMSE, and FAB.